CONGRESS PHARMA: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
CONGRESS PHARMA
Largest movements
- Receivables within one year -€98,472
down €98,472 (-72.5%), from €135,899 to €37,428
of which Trade receivables: -€99,338
- Cash +€34,944
up €34,944 (+450.7%), from €7,754 to €42,698
mainly Receivables within one year (+€98,472)
- Trade debts -€63,227
down €63,227 (-46.7%), from €135,406 to €72,178
- Gross operating margin +€11,095
up €11,095 (+2455.5%), from €452 to €11,546
- Other operating charges +€8,035
up €8,035 (+1004.3%), from €800 to €8,835
- Staff costs +€7,938
up €7,938, from -€7,938 to €0
- Taxes +€2,782
up €2,782, from €0 to €2,782
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €146,099 | €82,571 | -€63,528 | -43.5% |
| Fixed assets | 21/28 | €2,446 | €2,446 | = | 0.0% |
| Financial fixed assets | 28 | €2,446 | €2,446 | = | 0.0% |
| Current assets | 29/58 | €143,653 | €80,125 | -€63,528 | -44.2% |
| Amounts receivable within one year | 40/41 | €135,899 | €37,428 | -€98,472 | -72.5% |
| Trade receivables | 40 | €118,448 | €19,111 | -€99,338 | -83.9% |
| Other amounts receivable | 41 | €17,451 | €18,317 | +€866 | +5.0% |
| Cash at bank and in hand | 54/58 | €7,754 | €42,698 | +€34,944 | +450.7% |
| Total equity and liabilities | 10/49 | €146,099 | €82,571 | -€63,528 | -43.5% |
| Equity | 10/15 | €10,694 | €10,393 | -€301 | -2.8% |
| Contributions | 10/11 | €1 | €1 | = | 0.0% |
| Profit (loss) carried forward | 14 | €10,693 | €10,392 | -€301 | -2.8% |
| Amounts payable | 17/49 | €135,406 | €72,178 | -€63,227 | -46.7% |
| Amounts payable within one year | 42/48 | €135,406 | €72,178 | -€63,227 | -46.7% |
| Trade debts | 44 | €135,406 | €72,178 | -€63,227 | -46.7% |
| Suppliers | 440/4 | €135,406 | €72,178 | -€63,227 | -46.7% |
| Taxes, remuneration and social security | 45 | €0 | - | = | |
| Remuneration and social security | 454/9 | €0 | - | = | |
| Other amounts payable | 47/48 | €0 | - | = | |
| Remuneration, social security and pensions | 62 | -€7,938 | €0 | +€7,938 | |
| Other operating charges | 640/8 | €800 | €8,835 | +€8,035 | +1004.3% |
| Gross operating margin | 9900 | €452 | €11,546 | +€11,095 | +2455.5% |
| Operating profit (loss) | 9901 | €7,590 | €2,712 | -€4,878 | -64.3% |
| Financial income | 75/76B | €0 | - | = | |
| Recurring financial income | 75 | €0 | - | = | |
| Financial charges | 65/66B | €179 | €231 | +€52 | +28.9% |
| Recurring financial charges | 65 | €179 | €231 | +€52 | +28.9% |
| Profit (loss) for the period before taxes | 9903 | €7,411 | €2,481 | -€4,930 | -66.5% |
| Income taxes | 67/77 | €0 | €2,782 | +€2,782 | |
| Profit (loss) for the period | 9904 | €7,411 | -€301 | -€7,712 | |
| Profit (loss) for the period to be appropriated | 9905 | €7,411 | -€301 | -€7,712 |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 7 October 2026 via checked.be.